Ekso Bionics Holdings, Inc. (EKSO): Price and Financial Metrics

Ekso Bionics Holdings, Inc. (EKSO): $1.34

0.02 (+1.52%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

EKSO Price/Volume Stats

Current price $1.34 52-week high $3.13
Prev. close $1.32 52-week low $0.62
Day low $1.32 Volume 42,800
Day high $1.39 Avg. volume 227,155
50-day MA $1.99 Dividend yield N/A
200-day MA $1.40 Market Cap 23.99M

EKSO Stock Price Chart Interactive Chart >

EKSO Stock Summary

  • EKSO has a market capitalization of $37,152,875 -- more than approximately just 12.24% of US stocks.
  • With a year-over-year growth in debt of 119.66%, EKSO BIONICS HOLDINGS INC's debt growth rate surpasses 92.78% of about US stocks.
  • The volatility of EKSO BIONICS HOLDINGS INC's share price is greater than that of 84.73% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to EKSO BIONICS HOLDINGS INC, a group of peers worth examining would be IRIX, ASYS, LUNG, RWLK, and DMTK.
  • EKSO's SEC filings can be seen here. And to visit EKSO BIONICS HOLDINGS INC's official web site, go to www.eksobionics.com.

EKSO Valuation Summary

  • EKSO's EV/EBIT ratio is -2.2; this is 115.07% lower than that of the median Healthcare stock.
  • Over the past 119 months, EKSO's price/earnings ratio has gone up 0.5.

Below are key valuation metrics over time for EKSO.

Stock Date P/S P/B P/E EV/EBIT
EKSO 2023-12-29 2.1 2.3 -2.3 -2.2
EKSO 2023-12-28 1.6 1.8 -1.8 -1.6
EKSO 2023-12-27 1.4 1.6 -1.6 -1.4
EKSO 2023-12-26 1.4 1.6 -1.6 -1.5
EKSO 2023-12-22 1.4 1.6 -1.6 -1.5
EKSO 2023-12-21 1.3 1.5 -1.5 -1.4

EKSO Growth Metrics

    Its year over year cash and equivalents growth rate is now at -26.97%.
  • Its 2 year net cashflow from operations growth rate is now at -8.48%.
  • Its year over year revenue growth rate is now at 27.65%.
EKSO's revenue has moved up $6,266,000 over the prior 67 months.

The table below shows EKSO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13.437 -14.119 -14.765
2022-06-30 13.157 -14.004 -12.419
2022-03-31 11.903 -13.362 -10.714
2021-12-31 11.246 -11.156 -9.764
2021-09-30 9.424 -9.821 -10.877
2021-06-30 9.272 -8.616 -6.467

EKSO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EKSO has a Quality Grade of D, ranking ahead of 7.97% of graded US stocks.
  • EKSO's asset turnover comes in at 0.242 -- ranking 100th of 104 Machinery stocks.
  • MOG.A, DRQ, and CECE are the stocks whose asset turnover ratios are most correlated with EKSO.

The table below shows EKSO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.242 0.615 -1.072
2021-03-31 0.303 0.608 -2.750
2020-12-31 0.426 0.571 -2.648
2020-09-30 0.489 0.538 -2.401
2020-06-30 0.529 0.511 -2.663
2020-03-31 0.556 0.493 -1.145

EKSO Price Target

For more insight on analysts targets of EKSO, see our EKSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.00 Average Broker Recommendation 1.5 (Moderate Buy)

Ekso Bionics Holdings, Inc. (EKSO) Company Bio


Founded in 2005 in Richmond, California, Ekso Bionics Holdings Inc employs approximately 92 people that design, develop, and sell wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets. The company’s first product, HULC was developed for the military in partnership with Lockheed Martin, enhancing soldier capabilities to allow them to carry heavier loads over further distances. The EksoNR is currently the only FDA-cleared exoskeleton for treatment of ABI, helping physical therapists, physiatrists, and doctors to clinically rehabilitate patients. The company’s CEO is Jack Peurach, who served as Executive Vice President, Products for SunPower Corp before becoming Ekso’s Chief Executive Officer.


EKSO Latest News Stream


Event/Time News Detail
Loading, please wait...

EKSO Latest Social Stream


Loading social stream, please wait...

View Full EKSO Social Stream

Latest EKSO News From Around the Web

Below are the latest news stories about EKSO BIONICS HOLDINGS INC that investors may wish to consider to help them evaluate EKSO as an investment opportunity.

Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal

SAN RAFAEL, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding (“PDAC”) contractor for the Centers for Medicare & Medicaid Services (“CMS”) has completed its review of the Ekso Indego Personal and approved use of Healthcare Common Procedure Coding System (“HCPCS”) Code K1007 to bill Medicare for such device. CM

Yahoo | December 12, 2023

Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29

SAN RAFAEL, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Company will participate at the Centers for Medicare & Medicaid Services’ (“CMS”) Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023, to discuss appropriate Medicare payment for the Ekso Indego Personal. “We appreciate CMS for providing Ekso with

Yahoo | November 16, 2023

Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal

Ruling Could Significantly Expand Use of Ekso Indego Personal in Home and Community Markets SAN RAFAEL, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, announces that the Centers for Medicare & Medicaid Services (“CMS”) finalized its Calendar Year 2024 Home Health Prospective Payment System Rule CMS-1780 (“2024 Home Health Rule”), which includes exoskeletons in the M

Yahoo | November 2, 2023

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call Transcript

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call Transcript October 26, 2023 Ekso Bionics Holdings, Inc. beats earnings expectations. Reported EPS is $-0.24, expectations were $-0.31. Operator: Greetings, and welcome to the Ekso Bionics Quarter Three 2023 Financial Results Call. At this time all participants are in a listen-only mode. A brief question-and-answer session […]

Yahoo | October 27, 2023

Q3 2023 Ekso Bionics Holdings Inc Earnings Call

Q3 2023 Ekso Bionics Holdings Inc Earnings Call

Yahoo | October 27, 2023

Read More 'EKSO' Stories Here

EKSO Price Returns

1-mo -34.31%
3-mo -20.24%
6-mo 95.31%
1-year -2.90%
3-year -80.47%
5-year -96.34%
YTD -46.40%
2023 110.08%
2022 -55.09%
2021 -56.77%
2020 4.52%
2019 -68.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!